Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
Clinical trial NCT04629846 · COMPLETED
Trial details
- NCT number
- NCT04629846
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-23
- Primary completion
- 2022-08-22
- Enrollment
- 517
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.